NIAID ACTIV-3 Study Investigating LY-CoV555 & Remdesivir Placed on Pause: Drug Safety Monitoring Board Move Based on Safety Concern

The ACTIV-3 clinical trial, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and a large group of collaborators, has been paused due to possible safety issues observed by the independent data safety monitoring board (DSMB). This federally...

Pin It on Pinterest